The role of inflammation in atrial fibrillation: A myth or a fact?

American Journal of the Medical Sciences

Volumn 338, Issue 6, 2009, Pages 494-499

  Toutouzas, Konstantinos ^a   Synetos, Andreas ^a,b   Drakopoulou, Maria ^a   Stefanadi, Elli ^a   Tousoulis, Dimitrios ^a   Lerakis, Stamatios ^b   Stefanadis, Christodoulos ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Embolism; Inflammation; Prevention; Stroke

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; DEXAMETHASONE; ENALAPRIL; INTERLEUKIN 6; METHYLPREDNISOLONE; PLACEBO; SIMVASTATIN; TRANDOLAPRIL; AUTACOID; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIARRHYTHMIC ACTIVITY; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART MUSCLE REFRACTORY PERIOD; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MICROALBUMINURIA; MORBIDITY; MYOCARDITIS; OXIDATIVE STRESS; PERICARDITIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINUS RHYTHM; THROMBOGENESIS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECT; INFLAMMATION; POSTOPERATIVE COMPLICATION; THROMBOSIS;

ANTI-ARRHYTHMIA AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ELECTRIC COUNTERSHOCK; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, CARDIOVASCULAR; POSTOPERATIVE COMPLICATIONS; RENIN-ANGIOTENSIN SYSTEM; THROMBOSIS;

EID: 73949109294     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181b271a9     Document Type: Article

References (76)

1. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98: 946-952
2. Becker RC. Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. J Thromb Thrombolysis 2005;19:71-75
3. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-149
4. Toutouzas K, Drakopoulou M, Dilaveris P, et al. Inflammation in lone atrial fibrillation: new insights by coronary sinus thermography. Int J Cardiol 2009;134:345-350
5. Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA 1976;235:39-41.
6. Morgera T, Di Lenarda A, Dreas L, et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J 1992;124:455-467
7. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-3548
8. Conway DS, Buggins P, Hughes E, et al. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 2004;43:2075-2082 (Pubitemid 38686805)
9. Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005;95: 764-767
10. Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? Jpn Heart J 2004;45:441-445
11. Conway DS, Buggins P, Hughes E, et al. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. Am J Cardiol 2004;94:508-510
12. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-3010
13. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001;104:2886-2891
14. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004;25:1100-1107
15. Anderson JL, Allen Maycock CA, Lappe DL, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004;94:1255-1259
16. Asselbergs FW, van den Berg MP, Diercks GF, et al. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol 2005;98:73-77
17. Korantzopoulos P, Kolettis T, Siogas K, et al. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit 2003;9:RA225-RA229.
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454
19. Gaudino M, Andreotti F, Zamparelli R, et al. The-174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003;108(suppl 1):II195-II199.
20. Watanabe E, Arakawa T, Uchiyama T, et al. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006;108:346-353
21. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol 2001;56:375-380
22. Korantzopoulos P, Kolettis TM, Kountouris E, et al. Variation of inflammatory indexes after electrical cardioversion of persistent atrial fibrillation. Is there an association with early recurrence rates? Int J Clin Pract 2005;59:881-885 (Pubitemid 43918357)
23. Toutouzas K, Drakopoulou M, Markou V, et al. Increased coronary sinus blood temperature: correlation with systemic inflammation. Eur J Clin Invest 2006;36:218-223
24. Toutouzas K, Stougiannos P, Drakopoulou M, et al. Coronary sinus thermography in idiopathic dilated cardiomyopathy: correlation with systemic inflammation and left ventricular contractility. Eur J Heart Fail 2007;9:168-172
25. Stefanadis C, Tsiamis E, Vaina S, et al. Temperature of blood in the coronary sinus and right atrium in patients with and without coronary artery disease. Am J Cardiol 2004;93:207-210
26. Davidenko JM, Pertsov AV, Salomonsz R, et al. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 1992;355:349-351
27. Ikeda T, Czer L, Trento A, et al. Induction of meandering functional reentrant wave front in isolated human atrial tissues. Circulation 1997; 96:3013-3020
28. Konings KT, Kirchhof CJ, Smeets JR, et al. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994;89: 1665-1680
29. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964;67:200-220
30. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666
31. Chen SA, Tai CT, Yu WC, et al. Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1999;10:328-335
32. Dilaveris P, Giannopoulos G, Synetos A, et al. The role of renin angiotensin system blockade in the treatment of atrial fibrillation. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:387-403.
33. Allessie MA. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998;9:1378-1393
34. Tieleman RG, Van Gelder IC, Crijns HJ, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillationinduced electrical remodeling of the atria? J Am Coll Cardiol 1998;31: 167-173
35. Corradi D, Callegari S, Benussi S, et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Hum Pathol 2005;36:1080-1089
36. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54:361-379 (Pubitemid 34327915)
37. Corradi D, Callegari S, Maestri R, et al. Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008;5:782-796
38. Schotten U, Duytschaever M, Ausma J, et al. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation 2003;107:1433-1439
39. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic level in human cardiac muscle. Evidence for electrical uncoupling of side-to-side fiber connections with increasing age. Circ Res 1986;58:356-371
40. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100:87-95.
41. Tanaka K, Zlochiver S, Vikstrom KL, et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007;101:839-847
42. Verheule S, Sato T, Everett T IV, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-1465
43. Verheule S, Wilson E, Everett T IV, et al. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 2003;107: 2615-2622
44. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008;51:802-809
45. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96:1180-1184
46. Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. Jpn Circ J 1998;62:837-843
47. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104:174-180
48. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res 2003;111:137-142
49. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612-2617
50. Cardin S, Li D, Thorin-Trescases N, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res 2003;60: 315-325
51. Shinagawa K, Mitamura H, Takeshita A, et al. Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. J Am Coll Cardiol 2000;35:246-253
52. Webster MW, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985;56:566-569
53. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100: 376-380
54. Pedersen OD, Bagger H, Kober L, et al. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999;20:748-754 (Pubitemid 29209908)
55. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107:2926-2931 (Pubitemid 36736634)
56. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106: 331-336
57. Madrid AH, Escobar C, Rebollo JM, et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev 2003;7:243-246
58. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004;5:114-120
59. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-2098
60. Anne W, Willems R, Van der Merwe N, et al. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 2004;90:1025-1030
61. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62:105-111
62. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74:75-84.
63. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345
64. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92:1379-1383
65. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-1461
66. Chaney MA, Nikolov MP, Blakeman B, et al. Pulmonary effects of methylprednisolone in patients undergoing coronary artery bypass grafting and early tracheal extubation. Anesth Analg 1998;87:27-33.
67. Yared JP, Starr NJ, Torres FK, et al. Effects of single dose, postinduction dexamethasone on recovery after cardiac surgery. Ann Thorac Surg 2000;69:1420-1424
68. Goldstein RN, Ryu K, Khrestian C, et al. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 2008;19:74-81.
69. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143
70. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126
71. Conway DS, Buggins P, Hughes E, et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004;148:462-466
72. Roldan V, Marin F, Blann AD, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003;24:1373-1380
73. Burstein SA, Peng J, Friese P, et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 1996;14(suppl 1):154-162
74. Amrani DL. Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul Fibrinolysis 1990;1:443-446
75. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818
76. Acevedo M, Corbalan R, Braun S, et al. C-reactive protein and atrial fibrillation: "evidence for the presence of inflammation in the perpetuation of the arrhythmia". Int J Cardiol 2006;108:326-331